Tag: Nivolumab

1. The glucocorticoid-induced TNF receptor-related protein agonist, BMS-986156, is safe and tolerable as monotherapy and in combination with nivolumab. Evidence Rating Level: 2 (Good) Although immune checkpoint inhibitors (ICI) have shown clinical efficacy in a wide variety of cancers, a significant portion remain unresponsive to checkpoint blockade. Therefore, new strategies for...
Association of Sex With Outcomes in Patients Undergoing Percutaneous Coronary Intervention: A Subgroup Analysis of the GLOBAL LEADERS Randomized Clinical Trial 1. Bleeding after percutaneous coronary intervention (PCI) was more common in women, but the effect of two antiplatelet strategies on death and new Q-wave myocardial infarction following PCI did...
1. Nivolumab and bevacizumab combination therapy appears to be efficacious in relapsed epithelial ovarian cancer, especially in patients with platinum-sensitive disease. Evidence Rating Level: 2 (Good) Although previous investigations have indicated that the immune system plays an important role in ovarian cancer control, results from trials thus far on single-agent immune...
1. Nivolumab and bevacizumab combination therapy appears to be efficacious in relapsed epithelial ovarian cancer, especially in patients with platinum-sensitive disease. Evidence Rating Level: 2 (Good) Although previous investigations have indicated that the immune system plays an important role in ovarian cancer control, results from trials thus far on single-agent immune...
Oxaliplatin-Based Adjuvant Chemotherapy for Rectal Cancer After Preoperative Chemoradiotherapy (ADORE): Long-Term Results of a Randomized Controlled Trial 1. Adjuvant FOLFOX improves disease-free survival in patients with pathologic Stage II or III rectal cancer after upfront surgery and preoperative chemoradiotherapy, but is associated with a higher rate of adverse events. Evidence...
1. In a phase II clinical trial of 20 patients with platinum-resistant ovarian cancer, the use of nivolumab, a monoclonal antibody against programmed-death 1 (PD-1) receptor, demonstrated positive efficacy and tolerability. Evidence Rating Level: 2 (Good) Study Rundown: Due to its frequent diagnosis at advanced stages, ovarian cancer carries the highest...
Image: PD In this section, we will highlight the key high-impact studies, updates, and analyses published in medicine during the past week. Geographic Variation in Cardiovascular Procedure Use Among Medicare Fee-for-Service vs Medicare Advantage Beneficiaries  In this retrospective analysis of patients in capitated and fee-for-service Medicare plans, investigators found the capitated Medicare...
Image: PD              1. Combination therapy of nivolumab and ipilimumab achieved rapid and deep tumor regression in a subset of metastatic melanoma patients. 2. The therapy is associated with significant side effects that are comparable to monotherapies. Evidence Rating Level: 2 (Good)  Study Rundown: This study suggests that...